Imitrex, Sumatriptan News

OptiNose AS Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device YARDLEY, Pa.-- --The first patients have been successfully enrolled in a phase III study involving the intranasal delivery of sumatriptan powder using the OptiNose bi-directional technology.

The failure of the Libi-Gel trial rocked the stock of Antares and caused it to drop from around $2.62 to $1.67, with a subsequent recovery to $2.40. I think that this reaction failed to recognize the broad potential of the Antares product line beyond Libi-Gel. In particular, I think that the market is not giving sufficient value to Antares' ... (more)

Given this action, NuPathe expects the patent to issue within the next few months.